Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ananda PharmaSTU:1FX Debt-to-Equity is 2.69 as of Jul. 2025, which is at its 10-year median of 2.69. The stock has 5 warning signs investors should review. Among 810 Drug Manufacturers companies, Ananda Pharma ranks worse than 96.79% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ananda Pharma's Debt-to-Equity or its related term are showing as below:
STU:1FX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.8 Med: 2.69 Max: 9.49
Current: 2.69
During the past 7 years, the highest Debt-to-Equity Ratio of Ananda Pharma was 9.49. The lowest was -0.80. And the median was 2.69.
STU:1FX's Debt-to-Equity is ranked worse than 96.79% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs STU:1FX: 2.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ananda Pharma Debt-to-Equity Related Terms
Ananda Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ananda Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1FX vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ananda Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ananda Pharma Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ananda Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ananda Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ananda Pharma (STU:1FX) has a Debt-to-Equity of 2.69 as of Jul. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ananda Pharma and its competitors. This is near median its historical median of 2.69. According to the industry distribution chart, Ananda Pharma ranks #784 out of 810 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Ananda Pharma's Debt-to-Equity too high?
Ananda Pharma's current Debt-to-Equity of 2.69 is near median its 10-year median of 2.69. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Ananda Pharma's value of 2.69 is 860.7% above this industry median. Based on the distribution chart, Ananda Pharma ranks #784 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ananda Pharma's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ananda Pharma ranks #784 out of 810 companies for Debt-to-Equity. This places Ananda Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Ananda Pharma's value of 2.69 is 860.7% above this benchmark. While the company's 10-year median is 2.69 vs. the industry median of 0.28, Ananda Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ananda Pharma's current Debt-to-Equity of 2.69 is 860.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ananda Pharma and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ananda Pharma's current Debt-to-Equity is 2.69, which is near median its own 10-year median of 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ananda Pharma stock overvalued right now?
Ananda Pharma (STU:1FX) has a current Debt-to-Equity of 2.69. The current Debt-to-Equity is 2.69, which is near median its 10-year median of 2.69 and 860.7% above the Drug Manufacturers industry median of 0.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ananda Pharma (STU:1FX), the current Debt-to-Equity is 2.69 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ananda Pharma PLC is a UK-based biopharmaceutical company developing regulatory-approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy-induced peripheral neuropathy (funded by NIHR).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1FX has been successfully added to your 
